Tadalafil for Health & Longevity

Evidence Review created on 10/25/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Cialis, Adcirca, Alyq, Talmanco, Tadliq, IC351

Motivation

Tadalafil (Cialis) is a prescription medication taken by mouth, best known as a treatment for erectile dysfunction. It blocks an enzyme that breaks down a chemical messenger that relaxes the muscle in blood-vessel walls, so blood vessels widen in the penis and elsewhere in the body. Because a single dose acts for more than a day and generic versions are inexpensive, low daily doses are practical.

Besides its approved uses, tadalafil has drawn the attention of health-focused adults because large health-record studies have asked whether men who take it differ in rates of heart disease and dementia. Online clinics now offer low daily doses to men and women who have none of the approved conditions.

This review examines the evidence for and against tadalafil as a health and longevity intervention: its established and proposed benefits, its risks and interactions, how it is dosed and monitored, and how strong and how independent the underlying studies are.

Benefits - Risks - Protocol - Conclusion

This section lists overview content from expert commentators and academic narrative reviews on tadalafil and its drug class.

No relevant content on tadalafil was found from Rhonda Patrick (the FoundMyFitness site search was blocked or failed to load on every retrieval tier, and web searches returned nothing) or Chris Kresser (the site search returned no results). Beyond the episode listed above, Peter Attia mentions tadalafil only in a single paragraph of an article on erectile dysfunction as a cardiovascular marker (Peter Attia erectile dysfunction article). Life Extension mentions tadalafil only briefly within its protocols (Life Extension erectile dysfunction protocol, Life Extension prostate-enlargement protocol), and Lifespan.io only in a news report on a resveratrol study in aged rats (Lifespan.io resveratrol news report); none of these is an in-depth overview, so four items are listed.

Grokipedia

  • Tadalafil

    A broad encyclopedic overview of tadalafil’s indications, doses, pharmacokinetics (how the body absorbs and clears it), development by Lilly and ICOS, and safety profile, useful as quick orientation.

Examine

No Examine article on tadalafil exists. Examine.com does not typically cover prescription medications, and its site search returns no results for tadalafil.

ConsumerLab

No dedicated ConsumerLab article on tadalafil exists. ConsumerLab does not typically cover prescription medications; its tadalafil-related content is limited to a members’ Q&A on supplement interactions with Viagra or Cialis and recall notices for supplements adulterated with tadalafil.

Systematic Reviews

This section lists systematic reviews and meta-analyses on tadalafil’s main benefits and its most debated risk.

Mechanism of Action

Tadalafil blocks phosphodiesterase type 5 (PDE5, an enzyme that breaks down cyclic guanosine monophosphate, or cGMP, the messenger that relaxes smooth muscle). It thereby amplifies the nitric oxide–cGMP pathway (the signaling chain by which nitric oxide, NO, a gas released by nerves and vessel linings, widens blood vessels). With PDE5 blocked, cGMP persists, so penile erectile tissue, arteries, prostate and bladder muscle, and lung arteries relax more fully when NO is released. Because sexual stimulation is needed to release NO in the penis, the drug does not trigger erections on its own, and its mechanism in prostate symptoms is not established, according to the US Food and Drug Administration (FDA) prescribing information (CIALIS FDA label).

Key pharmacological properties (CIALIS FDA label):

  • Half-life: about 17.5 hours in healthy adults; stable blood levels after 5 days of daily dosing.
  • Selectivity: over 10,000-fold for PDE5 versus PDE1–4 and PDE7 (related enzymes elsewhere in the body); 700-fold versus PDE6 (the retinal light-sensing enzyme); only 14- to 40-fold versus PDE11 (an enzyme in prostate, testis and skeletal muscle whose role is undefined).
  • Distribution: volume of distribution about 63 L, indicating tissue uptake; 94% bound to blood proteins.
  • Metabolism: mainly by CYP3A4 (a major drug-clearing liver enzyme) to an inactive breakdown product; excreted 61% in feces and 36% in urine.

Two explanations of users’ lower cardiovascular event rates compete: better endothelial function (vessel-lining health), or unknown factors behind why men seeking erectile treatment die less often, a caveat the study authors raise (NPR report).

Historical Context & Evolution

ICOS Corporation first tested tadalafil (IC351) for cardiovascular uses such as heart-related chest pain, then redirected it to erectile dysfunction after sildenafil, a same-class drug with the same chest-pain origin (NPR report), succeeded; Eli Lilly co-developed it (Grokipedia article). Tadalafil was first approved in the US in 2003 for erectile dysfunction (CIALIS FDA label); its long half-life distinguished it from shorter-acting rivals. Later approvals added once-daily dosing and prostate-related urinary symptoms (CIALIS FDA label) and, at 40 mg daily, pulmonary arterial hypertension (progressive narrowing of the lung arteries) (ADCIRCA FDA label).

Interest in health optimization grew from three findings. A small trial reported better vessel-lining function after weeks of dosing, an effect that persisted two weeks after stopping (Rosano 2005). Large record-based cohorts, one led by a paid consultant to Sanofi, reported fewer cardiovascular events, deaths and dementia among users (Kloner 2024, Jehle 2025). Not all results pointed one way: a Lilly-co-authored 48-week trial in boys with Duchenne muscular dystrophy (an inherited muscle-wasting disease) found no benefit on muscle function (Victor 2017, CIALIS FDA label), and a Medicare analysis found no dementia association (Desai 2022).

Opinion is still moving. In 2026 the Princeton Consensus Panel, a group of urologists and cardiologists, reportedly agreed that low-dose tadalafil is “appropriate” for some men at elevated atherosclerotic (artery-plaque) risk; its members include clinicians who prescribe the drug, its funding was not stated, and the recommendations are unpublished (NPR report). No randomized outcome trial has yet tested it.

Expected Benefits

High 🟩 🟩 🟩

Erectile Function ⚠️ Conflicted

Tadalafil improves erections in men with erectile dysfunction (ED) by preserving cGMP. A network meta-analysis of 118 randomized controlled trials (RCTs, studies that assign treatment by chance) by Yuan’s Hong Kong group ranked it among the most effective in its class (Yuan 2013); Porst’s pooled analysis of six RCTs, with co-authors employed by the manufacturer Eli Lilly, found benefit with daily 2.5–5 mg (Porst 2014). Pattanaik’s 89-man RCT of low-dose tadalafil found no difference from placebo (Pattanaik 2019). Net: the large body of positive trials outweighs this single null trial.

Magnitude: The International Index of Erectile Function erectile function domain (IIEF-EF, a validated 30-point erection score) improved by least-squares mean changes (model-adjusted averages) of 4.2 points with 2.5 mg and 5.4 points with 5 mg daily versus placebo (Porst 2014).

Urinary Symptoms of Prostate Enlargement ⚠️ Conflicted

Daily 5 mg eases lower urinary tract symptoms (LUTS: weak stream, urgency, night-time urination) from benign prostatic hyperplasia (BPH, non-cancerous prostate enlargement). Oelke’s RCT of 511 men, with Lilly co-authors, found relief similar to tamsulosin (an alpha-blocker, a drug that relaxes prostate muscle) plus an erectile benefit (Oelke 2012). Gacci’s Florence group pooled seven placebo-controlled RCTs (3,214 men) and found benefit (Gacci 2012). In men aged 75 or older, a Lilly-co-authored pooled analysis found no significant benefit (Oelke 2017). Net: consistent benefit below age 75, unproven above it.

Magnitude: International Prostate Symptom Score (IPSS, a validated 35-point symptom scale) 2.1 points lower than placebo at 12 weeks, with maximum urine flow 2.4 mL/s higher (Oelke 2012); pooled IPSS 2.8 points lower than placebo, without a pooled flow gain (Gacci 2012).

Blood Glucose Control in Type 2 Diabetes

Two independent placebo-controlled RCTs found modestly lower glycated hemoglobin (HbA1c, a three-month blood-glucose average): Lee’s Korean group tested 5 mg daily for six months in 68 men with diabetes and ED (Lee 2022), and Fryk’s Swedish group tested 20 mg daily for six weeks in 18 adults, with partial Lilly funding (Fryk 2023). Fryk found no change in whole-body insulin resistance, so the mechanism is unclear. Both trials were small and short, and people without diabetes were not studied.

Magnitude: HbA1c 2.50 mmol/mol lower than placebo (95% confidence interval, CI, the range likely to contain the true effect: −4.20 to −0.78) after six weeks (Fryk 2023); change of −0.14% versus +0.20% with placebo over six months (Lee 2022).

Ureteral Stone Passage ⭕️ Not Central to Health & Longevity

By relaxing ureter muscle, tadalafil helps stones lodged in the lower ureter (the tube from kidney to bladder) pass. Meta-analyses of RCTs by Bai’s Sichuan group (6 trials, 921 patients) (Bai 2017) and Belkovsky’s São Paulo group (11 trials, 1,330 patients) (Belkovsky 2023) both found higher expulsion rates than with tamsulosin. This bears on acute stone episodes, not on aging.

Magnitude: Stone expulsion relative risk (RR, ratio of event rates) 1.16 versus tamsulosin (95% CI 1.05–1.29) (Bai 2017).

Medium 🟩 🟩

Cardiovascular Events and All-Cause Mortality

Men with ED who took tadalafil had fewer major adverse cardiovascular events (MACE: heart attack, stroke, revascularization (artery-reopening procedures), unstable angina (worsening chest pain), heart failure, cardiovascular death) and lower overall mortality than matched non-users in Kloner’s Sanofi-linked claims cohort of 29,168 men (Kloner 2024); Jehle’s cohort of 509,788 men found fewer heart attacks, strokes and deaths (Jehle 2025); a class meta-analysis agreed (Soulaidopoulos 2024). All data are observational: men who seek erectile treatment may be healthier or more health-engaged, and no RCT has tested this outcome.

Magnitude: MACE hazard ratio (HR, relative event rate over time) 0.81 (95% CI 0.70–0.94) and all-cause mortality HR 0.56 (95% CI 0.43–0.74) versus men unexposed to any PDE5 inhibitor (Kloner 2024).

Exercise Capacity in Pulmonary Arterial Hypertension ⭕️ Not Central to Health & Longevity

In pulmonary arterial hypertension (PAH, progressive narrowing of the lung arteries), tadalafil 40 mg daily improved walking distance and delayed clinical worsening in Galiè’s PHIRST trial of 405 patients, which had Lilly co-authors (Galiè 2009). Galiè also led AMBITION, funded by Gilead and GlaxoSmithKline, where starting tadalafil with ambrisentan (a lung-artery-relaxing drug) outperformed either alone (Galiè 2015). Barnes’s Cochrane review confirmed functional gains and fewer deaths but pooled other PDE5 inhibitors, so it is indirect for tadalafil (Barnes 2019). This bears on a rare lung-vessel disease, not on healthy aging.

Magnitude: Six-minute walk distance 33 m more than placebo (95% CI 15–50 m) (Galiè 2009); across the class, 48 m more than placebo (95% CI 40–56 m) and a number needed to treat (NNT, patients treated to prevent one event) of 32 to prevent one death over about 14 weeks (Barnes 2019).

Low 🟩

Vascular Endothelial Function ⚠️ Conflicted

Rosano’s 32-man RCT (20 mg alternate days, high cardiovascular risk) found improved flow-mediated dilation (FMD, ultrasound-measured artery widening) (Rosano 2005); Pattanaik’s 89-man RCT (low dose, younger men with ED) found no difference from placebo (Pattanaik 2019), possibly reflecting dose and population. A class-wide meta-analysis reported improvement (Zhang 2025). Net: unconfirmed.

Magnitude: FMD rose 2.43 versus 2.83 percentage points with placebo, a non-significant difference (Pattanaik 2019); across the class, FMD 2.47% higher than placebo (95% CI 1.24–3.71) (Zhang 2025).

Blood Pressure Lowering ⚠️ Conflicted

Zhang’s class-wide meta-analysis of 63 RCTs found lower blood pressure (Zhang 2025), indirect for tadalafil because other agents were pooled. The label reports only 1.6/0.8 mm Hg with 20 mg (CIALIS FDA label); Ölmestig’s 3-month RCT found no difference (Ölmestig 2025). Net: a small, inconsistent effect.

Magnitude: Systolic pressure 2.80 mm Hg lower than placebo (95% CI 1.37–4.24) and diastolic 1.80 mm Hg lower (95% CI 1.22–2.37), all PDE5 inhibitors pooled (Zhang 2025).

Cardiac Structure and Function

Giannetta’s meta-analysis of 24 placebo-controlled RCTs found continuous PDE5 inhibition reduced heart-muscle mass in left ventricular hypertrophy (thickened heart wall) and raised ejection fraction (share of blood pumped per beat) (Giannetta 2014). Pooling several agents makes this indirect. A tadalafil trial improved cardiac twisting only in men (Pofi 2022).

Magnitude: Cardiac mass 12.21 g/m² lower (95% CI 5.57–18.85) in left ventricular hypertrophy and ejection fraction 3.56 percentage points higher (95% CI 1.79–5.33) than placebo, all PDE5 inhibitors pooled (Giannetta 2014).

Dementia Risk ⚠️ Conflicted

Jehle’s cohort linked tadalafil to less dementia (Jehle 2025); Adesuyan’s cohort agreed class-wide (Adesuyan 2024). Desai’s Medicare study, using another drug’s users as controls to limit healthier-user bias, found none (Desai 2022), a meta-analysis no significant tadalafil effect (Abouelmagd 2024), and an RCT no cognitive change (Ölmestig 2025). Net: unproven.

Magnitude: Dementia RR 0.68 with tadalafil versus matched non-users over three years (Jehle 2025); Alzheimer and related dementia HR 0.99 (95% CI 0.69–1.43) for PDE5 inhibitors versus comparator drugs (Desai 2022).

Raynaud’s Phenomenon ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In secondary Raynaud’s phenomenon (cold-triggered finger-artery spasm), Roustit’s meta-analysis of six RCTs, three with tadalafil, found fewer, shorter attacks (Roustit 2013); pooling makes this indirect. Schiopu’s 39-woman tadalafil RCT found no placebo difference (Schiopu 2009). It bears on finger circulation, not aging. Net: a modest class effect, unconfirmed for tadalafil.

Magnitude: Raynaud’s Condition Score 0.46 points lower (95% CI 0.17–0.74) and 0.49 fewer daily attacks (95% CI 0.28–0.71) versus placebo, all PDE5 inhibitors pooled (Roustit 2013).

Sperm Motility in Infertile Men ⭕️ Not Central to Health & Longevity

Tan’s meta-analysis of 11 studies (1,317 men) found higher sperm motility and more normally shaped sperm after acute PDE5-inhibitor use, but only in infertile men (Tan 2017). Pooling other agents makes this indirect for tadalafil. It bears on male fertility, not aging.

Magnitude: Percentage of motile sperm 6.89 points higher in infertile men versus 0.67 points (not significant) in men with normal fertility, and normally shaped sperm 12.15 points higher (95% CI 5.16–19.15) in infertile men, all PDE5 inhibitors pooled; pooled changes after treatment without a stated comparison group (no control group) (Tan 2017).

Premature Ejaculation ⭕️ Not Central to Health & Longevity

Zhang’s meta-analysis of six placebo-controlled RCTs, two with tadalafil, found longer time to ejaculation in men with premature ejaculation (very early ejaculation) but without erectile dysfunction (Zhang 2020). Pooling other agents makes this indirect for tadalafil. It bears on sexual function, not aging.

Magnitude: Time to ejaculation 2.60 minutes longer than placebo (95% CI 1.85–3.36), all PDE5 inhibitors pooled (Zhang 2020).

Speculative 🟨

Lower Inflammatory Markers

Cianciarulo’s class-wide meta-analysis of 20 RCTs found lower IL-6 and P-selectin (vascular inflammation markers) with use of 12 weeks or longer (Cianciarulo 2025). Both are unvalidated biomarkers, and pooling other agents makes this indirect.

Brain White-Matter Blood Flow

In cerebral small vessel disease (damage to tiny brain arteries), Yan’s meta-analysis of four RCTs found higher white-matter blood flow but no cognitive benefit (Yan 2026). This unvalidated biomarker comes from trials pooling sildenafil.

Benefit-Modifying Factors

  • Genetic polymorphisms: No genetic variant has been validated to modify tadalafil’s benefits; the label’s exposure modifiers are co-medications that inhibit or induce CYP3A4 (CIALIS FDA label).
  • Baseline testosterone: In hypogonadal (low-testosterone) non-responders, adding testosterone helped only when total testosterone was ≤3 ng/mL (Buvat 2011); in men with prostate symptoms, a Lilly-co-authored analysis found low testosterone did not blunt erectile response (Mulhall 2016).
  • Baseline severity: In severe ED, 44.5% on 5 mg daily reached a severity-specific clinically important improvement versus 11.6% on placebo, lower than in mild ED (Porst 2014).
  • Sex: Almost all data come from men. In diabetic heart muscle disease, 20 mg daily improved cardiac twisting motion in men but not women (Pofi 2022).
  • Pre-existing conditions: Diabetes lowers tadalafil exposure by about 19% (CIALIS FDA label); obese men and smokers reached clinically important erectile gains only with 5 mg (Porst 2014).
  • Age: Prostate-symptom benefit was not significant in men aged 75 or older, who had more illnesses and medications (Oelke 2017).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Headache, Dyspepsia, Back Pain, Myalgia and Flushing

These vessel-widening and smooth-muscle effects are the commonest adverse events: headache, dyspepsia (indigestion and reflux), back pain and myalgia (muscle aches, typically 12–24 hours after a dose), flushing and nasal congestion (CIALIS FDA label). Lilly’s label trials, Barnes’s Cochrane review (Barnes 2019) and Ölmestig’s independent 20 mg daily trial (Ölmestig 2025) all document them, with rates rising with dose. They are usually mild to moderate, and back pain typically resolves within 48 hours.

Magnitude: With 20 mg as needed, headache 15% versus 5% on placebo, dyspepsia 10% versus 1% and back pain 6% versus 3%; with 5 mg daily in prostate trials, headache 4.1% versus 2.3% and dyspepsia 2.4% versus 0.2% (CIALIS FDA label); any adverse event 76% versus 36% with 20 mg daily (Ölmestig 2025).

Medium 🟥 🟥

Symptomatic Low Blood Pressure with Nitrates, Doxazosin or Heavy Alcohol ⚠️ Conflicted

Tadalafil 20 mg lowers lying-down blood pressure 1.6/0.8 mm Hg versus placebo but adds to other vessel-widening drugs (CIALIS FDA label). Kloner’s Lilly-co-authored RCTs showed amplified falls with nitroglycerin (a nitrate heart-pain drug) for 24 but not 48 hours (Kloner 2003) and with single 20 mg doses plus doxazosin (Kloner 2004); Guillaume’s daily 5 mg RCT with doxazosin found none (Guillaume 2007). Five or more alcohol units caused orthostatic hypotension (a standing blood-pressure drop) in label studies. Net: nitrate and alcohol risks are firm, doxazosin risk mainly at higher doses.

Magnitude: Standing systolic pressure fell below 85 mm Hg in 28% with doxazosin plus tadalafil versus 6% with doxazosin plus placebo, an extra 9.8 mm Hg standing systolic fall (Kloner 2004).

Reduced Sperm Concentration ⚠️ Conflicted

In three manufacturer RCTs of daily dosing, mean sperm concentration fell versus placebo with 10 mg for 6 months and 20 mg for 9 months, but not with 20 mg for 6 months; the label calls the falls not clinically meaningful (CIALIS FDA label). In the 9-month trial, more men had large drops, though tadalafil met non-inferiority (shown not meaningfully worse) and hormones were unchanged (Hellstrom 2008). Net: a small, mostly reversible effect of long daily use.

Magnitude: A sperm-concentration fall of 50% or more in 12.6% versus 2.1% on placebo; 8 of 12 affected men on tadalafil returned to baseline after stopping (Hellstrom 2008).

Low 🟥

Nonarteritic Anterior Ischemic Optic Neuropathy ⚠️ Conflicted

NAION (sudden, often permanent vision loss from reduced optic-nerve blood flow) was about twice as likely shortly after use in Pfizer- and Lilly-funded case-crossover studies (each man serving as his own control) (Campbell 2015, Flahavan 2017); Penedones’s meta-analysis found no association (Penedones 2020). Net: a possible small, class-wide risk.

Magnitude: Odds ratio (OR, ratio of the odds of an event) 2.15 (95% CI 1.06–4.34) within five half-lives of use versus each man’s own earlier periods, a self-controlled design with no separate control group, estimated as three extra cases per 100,000 men aged 50 or older per year with weekly use (Campbell 2015); pooled OR 1.16 (95% CI 0.89–1.52) (Penedones 2020).

Sudden Sensorineural Hearing Loss

Sudden hearing loss of inner-ear origin, sometimes with tinnitus (ringing in the ears) and dizziness, appears in post-marketing reports and the label (CIALIS FDA label). Liu’s claims cohort found a small excess with class use (Liu 2018) but did not isolate tadalafil, so evidence for this compound is indirect.

Magnitude: Adjusted HR 1.25 (95% CI 1.01–1.55); 4.35 versus 2.38 cases per 10,000 person-years (people followed for one year each) for current use versus non-use, a risk difference of 1.97 per 10,000 person-years (Liu 2018).

Color Vision Changes ⚠️ Conflicted

Blurred or altered color vision, plausibly from weak inhibition of the retinal enzyme PDE6, is a rare label-listed adverse reaction (CIALIS FDA label). Cordell’s Lilly-sponsored 6-month RCT of 5 mg daily found no placebo difference in color discrimination or retinal function (Cordell 2009). Net: rare, without measurable retinal effect.

Magnitude: Color vision changes in under 0.1% of patients in label trials, with no placebo rate reported (CIALIS FDA label); no difference from placebo in color-discrimination errors after 6 months (Cordell 2009).

Retinal Vascular Occlusion and Serous Retinal Detachment

Retinal vein and artery occlusion (blockage of retinal blood vessels) are label-listed post-marketing reactions (CIALIS FDA label). Etminan’s US claims cohort linked regular use of the drug class to serous retinal detachment (fluid lifting the retina) but did not isolate tadalafil, so evidence for this compound is indirect (Etminan 2022).

Magnitude: Adjusted incidence rate ratio (ratio of event rates) 2.58 (95% CI 1.55–4.30) for serous retinal detachment and 1.44 (95% CI 0.98–2.12, not significant) for retinal vascular occlusion in regular users versus non-users, all PDE5 inhibitors pooled; incidence among users 3.8 (serous retinal detachment) and 8.5 (retinal vascular occlusion) cases per 10,000 person-years, with no non-user rate reported (Etminan 2022).

Melanoma ⚠️ Conflicted

Loeb’s meta-analysis found slightly more melanoma among users of the class, but without a dose-response and with a parallel basal-cell-cancer signal suggesting confounding (distortion by a third factor) by sun exposure (Loeb 2017). Kreuz’s update found no significant tadalafil-specific association (Kreuz 2025). Net: causation is unsupported.

Magnitude: RR 1.11 (95% CI 1.02–1.22) for all PDE5 inhibitors (Loeb 2017); tadalafil-specific OR 1.54 (95% CI 0.79–3.00), not significant (Kreuz 2025).

Cardiac Events During Use ⚠️ Conflicted

Heart attacks, sudden cardiac death and stroke have been reported after tadalafil, mostly in men with risk factors and often during sex (CIALIS FDA label). Jackson’s pooled analysis of 35 controlled trials, with Lilly co-authors, found no excess (Jackson 2004). Net: no drug-attributable excess shown.

Magnitude: Myocardial infarction (heart attack) 0.33 versus 0.41 per 100 patient-years (patients followed for one year each) on placebo (Jackson 2004).

Priapism

Priapism (a painful erection lasting over six hours) is rare but can permanently damage erectile tissue if untreated (CIALIS FDA label). King described a case after tadalafil requiring surgical shunting (King 2005). Sickle cell anemia, leukemia and multiple myeloma (a bone-marrow plasma-cell cancer) raise susceptibility.

Magnitude: Not quantified in available studies. The evidence consists of post-marketing and case reports without a known number of exposed users.

Serious Skin Reactions

Post-marketing reports include Stevens-Johnson syndrome (a severe blistering reaction of skin and mucous membranes) and exfoliative dermatitis (widespread peeling inflammation of the skin) (CIALIS FDA label). Fixed drug eruptions (rashes recurring at the same site with each dose) appear in case reports (Zhang 2024).

Magnitude: Not quantified in available studies. Only isolated post-marketing and case reports exist, without a comparison group.

Seizures and Transient Global Amnesia

Seizures and transient global amnesia (a sudden, temporary loss of memory for recent events) are label-listed post-marketing reactions (CIALIS FDA label). Case reports describe convulsive seizures in a young man (Calabrò 2013) and amnesia after a first dose (Schiefer 2005); causation is unproven.

Magnitude: Not quantified in available studies. Only post-marketing and case reports exist, without a known number of exposed users.

Speculative 🟨

Arteritis Signal from Animal Toxicology

Mice, rats and dogs given tadalafil developed vascular inflammation (arteritis) at exposures above human therapeutic levels (CIALIS FDA label). The basis is animal-only; no human data link tadalafil to arteritis.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic marker for tadalafil risk is established; exposure is driven mainly by co-medications that inhibit or induce CYP3A4, which can raise exposure more than four-fold (CIALIS FDA label).
  • Baseline blood pressure and kidney function: Resting hypotension below 90/50 mm Hg, uncontrolled hypertension, or creatinine clearance (a kidney filtration estimate) below 30 mL/min raise risk; exposure doubles at 30–80 mL/min (CIALIS FDA label).
  • Sex: In a 20 mg daily trial, 46% of women stopped treatment versus 16% of men (Ölmestig 2025); the CIALIS label states the drug is not indicated for women (CIALIS FDA label).
  • Eye and ear conditions: A “crowded” optic disc (a small optic-nerve head), prior NAION, or retinitis pigmentosa (an inherited retinal degeneration) raise ocular concern (CIALIS FDA label).
  • Cardiovascular conditions: Aortic stenosis (narrowed heart outflow valve), severe autonomic dysfunction (impaired automatic blood-pressure control) and recent heart attack or stroke heighten sensitivity to vessel widening (CIALIS FDA label).
  • Age: Adults aged 65 or older have about 25% higher exposure and more diarrhea (CIALIS FDA label); pooled trials showed no increase in cardiovascular adverse events in men aged 75 or older (Oelke 2017).

Key Interactions & Contraindications

Documented interactions:

  • Organic nitrates (nitroglycerin, isosorbide mononitrate, amyl nitrite): Absolute contraindication. Severe hypotension; the interaction lasted 24 hours and was absent at 48 hours (Kloner 2003). If a nitrate becomes medically essential, at least 48 hours must elapse under monitoring (CIALIS FDA label).
  • Guanylate cyclase stimulators (drugs that directly activate the cGMP-producing enzyme; riociguat): Absolute contraindication. Combined use can cause severe hypotension (CIALIS FDA label).
  • Alpha-blockers (doxazosin, terazosin, tamsulosin): After single 20 mg doses, doxazosin markedly augmented standing blood-pressure falls, tamsulosin little (Kloner 2004); with daily 5 mg, neither did (Guillaume 2007). Starting tadalafil at the lowest dose once stable on the alpha-blocker is the label approach (CIALIS FDA label).
  • Silodosin (a prostate-selective alpha-blocker): No interaction found: in a placebo-controlled crossover study, adding tadalafil 20 mg to silodosin 8 mg caused no clinically important orthostatic blood-pressure or heart-rate changes (MacDiarmid 2010).
  • Alfuzosin (a prostate-selective alpha-blocker): No interaction found: in a placebo-controlled crossover trial of 18 men, adding tadalafil 20 mg to alfuzosin 10 mg daily caused no clinically relevant fall in standing blood pressure (Giuliano 2006).
  • Antihypertensives (blood-pressure drugs; amlodipine, enalapril, metoprolol, bendrofluazide, angiotensin receptor blockers): Additional blood-pressure lowering of about 3–8 mm Hg systolic; checking standing blood pressure after starting mitigates dizziness (CIALIS FDA label). In a Hanmi Pharmaceutical-co-authored crossover study, amlodipine also raised tadalafil exposure by 57% (Kim 2022).
  • Oral minoxidil and other direct vessel-widening antihypertensives: The label states tadalafil can strengthen the blood-pressure-lowering effect of antihypertensives, risking dizziness or fainting; minoxidil itself was not studied. Checking standing blood pressure after starting mitigates this (CIALIS FDA label).
  • Alcohol (5 or more units): Orthostatic hypotension, dizziness and faster heart rate; a lower alcohol dose did not strengthen these effects, so keeping intake below 5 units on dosing days avoids them (CIALIS FDA label).
  • Potent CYP3A4 inhibitors (drugs that slow CYP3A4; ketoconazole, itraconazole, ritonavir): Ketoconazole raised tadalafil exposure by 312%, increasing side effects; the label caps daily use at 2.5 mg and as-needed use at 10 mg every 72 hours (CIALIS FDA label).
  • Moderate CYP3A4 inhibitors and grapefruit juice (erythromycin, grapefruit): Not specifically studied; the label states they would likely raise tadalafil exposure and side effects (CIALIS FDA label). Limiting grapefruit and using the lowest effective dose mitigate this.
  • CYP3A4 inducers (drugs that speed CYP3A4; rifampin, carbamazepine, phenytoin, phenobarbital): Rifampin cut exposure by 88%, likely reducing efficacy of daily dosing; no dose adjustment is specified (CIALIS FDA label).
  • Bosentan (a PAH drug that induces CYP3A4): Lowered tadalafil exposure by 41.5% in a Lilly study, potentially reducing efficacy (Wrishko 2008).
  • Ambrisentan (a lung-artery-relaxing PAH drug): No interaction found: in a Gilead crossover study, co-administration left tadalafil exposure unchanged and slightly lowered ambrisentan exposure, with no dose adjustment needed (Spence 2009).
  • Linagliptin (a diabetes drug): In a crossover study in healthy men, linagliptin raised tadalafil peak level and exposure, with more muscle pain and a lengthened QTc (a heart-rhythm interval) (Mourad 2019); monitoring or a lower tadalafil dose mitigates this.
  • Other PDE5 inhibitors (sildenafil, vardenafil, avanafil): Avoid. Additive vessel widening and side effects; combinations are unstudied (CIALIS FDA label).
  • Sexual-enhancement supplements adulterated with PDE5 inhibitors: Avoid. Hidden sildenafil or tadalafil can double the dose and interact with nitrates (ConsumerLab interaction answer, Tucker 2018).
  • L-arginine: Tested with daily tadalafil in a randomized trial of 108 men with diabetes, where the pair improved erectile scores more than either alone (El Taieb 2019); no pharmacokinetic study exists, so checking standing blood pressure after adding it mitigates possible additive lowering.
  • Antacids and H2 blockers (stomach-acid reducers; magnesium/aluminum hydroxide, nizatidine): No interaction found on exposure; antacids only slowed absorption (CIALIS FDA label).
  • Aspirin and warfarin: No interaction found: tadalafil did not lengthen aspirin’s bleeding time or change warfarin exposure or prothrombin time (a clotting test) (CIALIS FDA label).
  • Chlorpromazine (an antipsychotic with alpha-blocking action): A case report describes priapism needing a penile prosthesis after chlorpromazine taken 24 hours after tadalafil 20 mg (Arici 2025); checking new prescriptions for this pairing mitigates it.
  • Theophylline: A small 3 beats-per-minute heart-rate increase, without pharmacokinetic change (CIALIS FDA label).
  • Finasteride (a 5-alpha-reductase inhibitor, a drug that shrinks the prostate): Co-initiation for BPH is labeled for up to 26 weeks, because tadalafil’s added benefit wanes from week 4 and is unknown beyond week 26 (CIALIS FDA label).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • L-citrulline: Additive NO-cGMP signaling (it is converted to L-arginine, the NO source) could add to blood-pressure lowering and headache; introducing it separately and checking standing blood pressure mitigates this.
  • Dietary nitrate concentrates (beetroot juice concentrates, nitrate supplements): Additive NO supply could deepen vessel widening and blood-pressure falls; spacing and monitoring blood pressure mitigates this.
  • Icariin (horny goat weed extract, a weak PDE5 inhibitor): Additive PDE5 inhibition could raise side effects; avoiding stacking is the mitigating action.
  • St John’s wort: CYP3A4 induction could lower tadalafil exposure and efficacy, by analogy with rifampin; avoiding the combination, or watching for loss of effect, mitigates this.

Populations who should avoid Tadalafil:

  • Users of any organic nitrate or guanylate cyclase stimulator (CIALIS FDA label).
  • Myocardial infarction within the last 90 days; unstable angina or angina during intercourse; heart failure of New York Heart Association (NYHA) Class 2 or greater (a symptom-severity scale; Class 2 means symptoms with ordinary activity) within 6 months; uncontrolled arrhythmias; hypotension below 90/50 mm Hg; uncontrolled hypertension; stroke within 6 months (CIALIS FDA label).
  • Severe hepatic impairment (Child-Pugh Class C, a liver-failure severity grade) (CIALIS FDA label).
  • Creatinine clearance below 30 mL/min or hemodialysis, for once-daily use (CIALIS FDA label).
  • Hereditary degenerative retinal disorders, including retinitis pigmentosa (CIALIS FDA label).
  • Prior serious hypersensitivity to tadalafil (CIALIS FDA label).
  • Pulmonary veno-occlusive disease (blockage of the small lung veins) (ADCIRCA FDA label).
  • Prior NAION, unless anticipated benefit outweighs risk (CIALIS FDA label).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Low starting dose: Starting at 2.5 mg daily and moving to 5 mg only if tolerated limits headache, dyspepsia and back pain, which rise with dose (CIALIS FDA label).
  • Nitrate plan: Carrying a written note of tadalafil use prevents severe hypotension in emergencies; nitrates require at least 48 hours after the last dose and medical supervision (CIALIS FDA label).
  • Standing blood-pressure check: Measuring seated and standing blood pressure in the first week, especially with alpha-blockers or antihypertensives, detects orthostatic falls; resting pressure below 90/50 mm Hg is the label’s no-use threshold (CIALIS FDA label).
  • Alcohol limit: Keeping intake below 5 units on dosing days prevents orthostatic hypotension and dizziness (CIALIS FDA label).
  • CYP3A4 drug review: Checking new prescriptions for strong CYP3A4 inhibitors prevents toxic exposure; with them, daily dose stays at or below 2.5 mg (CIALIS FDA label).
  • Four-hour erection rule: An erection lasting over 4 hours prompts emergency care, preventing permanent erectile damage from priapism (CIALIS FDA label).
  • Vision and hearing stop rule: Sudden loss of vision or hearing means stopping all PDE5 inhibitors and seeking prompt care, limiting NAION and hearing-loss harm (CIALIS FDA label).
  • Back-pain management: Acetaminophen or anti-inflammatory drugs generally relieved tadalafil-related back pain and myalgia, which usually resolve within 48 hours (CIALIS FDA label).
  • Fertility check: Men planning conception can obtain a baseline and follow-up semen analysis, since daily 20 mg reduced sperm concentration in some men (Hellstrom 2008).
  • Skin surveillance: Annual skin examinations for those with melanoma risk factors address the unresolved melanoma association (Loeb 2017).
  • Supplement hygiene: Avoiding “male enhancement” products prevents hidden PDE5-inhibitor double dosing (Tucker 2018).

Therapeutic Protocol

Timing, titration steps (gradual dose increases) and other parameters without a citation reflect common practice.

  • Longevity-oriented daily dose: 2.5–5 mg once daily, the label ED and BPH dose (CIALIS FDA label), offered off-label for longevity by telehealth clinics such as AgelessRx, which sells it (NPR report).
  • Competing positions: Kloner calls the observational signal “very interesting”; Nissen holds that without randomized data the use is “pretty hard to justify”; the Princeton Consensus Panel, whose members include prescribing clinicians, called low dose “appropriate” for higher-risk men (NPR report).
  • Popularizers: Low-dose daily use for longevity has been promoted by figures including Andrew Huberman and Bryan Johnson and by online clinics (NPR report).
  • As-needed dosing for ED: 10 mg before sexual activity, adjusted to 5 or 20 mg, at most once daily; effect lasts up to 36 hours (CIALIS FDA label).
  • BPH dose: 5 mg once daily at about the same time each day (CIALIS FDA label).
  • PAH dose: 40 mg once daily, not divided (ADCIRCA FDA label).
  • Research doses: Trials of vascular and metabolic endpoints used 20 mg daily (Fryk 2023, Ölmestig 2025), with markedly more adverse events than placebo (76% versus 36% in ETLAS-2).
  • Time of day: Any time, with or without food (CIALIS FDA label); evening dosing is often chosen so that peak-level headache coincides with sleep.
  • Half-life: About 17.5 hours; daily dosing reaches steady state (stable blood levels) in 5 days at about 1.6-fold single-dose exposure (CIALIS FDA label).
  • Single versus split dosing: A single daily dose; the label advises against splitting CIALIS tablets (CIALIS FDA label) and dividing the 40 mg PAH dose (ADCIRCA FDA label).
  • Genetic polymorphisms: No pharmacogenetic dosing rule exists; co-medication with CYP3A4 inhibitors, not genotype, sets the 2.5 mg daily cap (CIALIS FDA label).
  • Sex differences: ED and BPH labeling covers men only; PAH labeling covers both sexes (ADCIRCA FDA label). Women stopped 20 mg daily far more often (Ölmestig 2025), favoring lower doses.
  • Age: No adjustment for age alone, though adults aged 65 or older have 25% higher exposure; the label’s lowest once-daily dose is 2.5 mg (CIALIS FDA label).
  • Baseline biomarkers: Creatinine clearance 30–50 mL/min calls for a 2.5 mg daily start; below 30 mL/min, daily use is not advised (CIALIS FDA label). In non-responders with testosterone at or below 3 ng/mL, adding testosterone improved response (Buvat 2011).
  • Pre-existing conditions: Mild or moderate liver impairment calls for caution with daily use and at most 10 mg as needed (CIALIS FDA label).

Discontinuation & Cycling

  • Duration: Approved uses are ongoing treatments, and the longevity rationale implies indefinite use; benefits are not disease-modifying, though improved vessel function persisted two weeks after stopping (Rosano 2005).
  • Withdrawal effects: No withdrawal or rebound syndrome is described in the label (CIALIS FDA label); erectile and urinary symptoms are expected to return toward baseline.
  • Tapering: Not required; stopping at once is the usual approach.
  • Cycling: No evidence supports cycling to maintain efficacy; with finasteride, the label limits combined BPH initiation to 26 weeks because added benefit wanes (CIALIS FDA label).
  • Planned pauses: A pause of at least 48 hours before anticipated nitrate use, such as cardiac procedures, avoids the nitrate interaction (Kloner 2003).
  • Fertility recovery: Most men with reduced sperm concentration on daily 20 mg returned to baseline within six months of stopping (Hellstrom 2008).

Sourcing and Quality

  • Prescription generics: FDA-approved generics are bioequivalent (delivering the same blood levels) to brand-name Cialis and typically cheaper (FDA generic drug facts). Cialis is made by Eli Lilly (CIALIS FDA label); Adcirca is marketed by United Therapeutics (ADCIRCA FDA label).
  • Licensed pharmacies: Buying from licensed pharmacies, including accredited online services, avoids counterfeit or mislabeled product, which can deliver wrong doses or contaminants.
  • Adulterated supplements: Sexual-enhancement supplements frequently contain undeclared PDE5 inhibitors and are not a substitute for tadalafil (Tucker 2018, ConsumerLab interaction answer).
  • Formulations: Tablets of 2.5, 5, 10 and 20 mg; an oral suspension (Tadliq) for PAH (TADLIQ FDA label); oral dispersible films performed like tablets in one ED trial (Motawi 2024).
  • Compounded products: Compounding pharmacies sell tadalafil troches (dissolving lozenges) and chewable combinations; compounded drugs are not FDA-approved (FDA compounding Q&A), so dose accuracy depends on the pharmacy.
  • Third-party testing: Not applicable to FDA-approved generics, which FDA requires to match the brand in active ingredient, strength and quality (FDA generic drug facts); it matters only for products sold outside pharmacies.

Practical Considerations

  • Time to effect: As-needed doses peak at a median 2 hours (CIALIS FDA label); in a Lilly-sponsored trial, daily 5 mg helped erections within 2 days (Seftel 2011); maximal daily effect may take 12 weeks (Buvat 2011); urinary symptoms eased within 1 week (Oelke 2012).
  • Common pitfalls: Expecting erections without sexual stimulation; combining with nitrates, including inhaled amyl nitrite; taking “male enhancement” supplements alongside; heavy drinking on dosing days; and reading observational mortality data as proof of causation.
  • Regulatory status: Prescription-only in the US, approved for ED, BPH and ED with BPH (CIALIS FDA label) and for PAH (ADCIRCA FDA label); it is not approved for cardiovascular prevention or longevity, making such use off-label.
  • Cost and access: Not exceptionally expensive; one telehealth longevity offering costs about $70 per month (NPR report), and generic pharmacy prices are typically lower.
  • Women: Use for longevity in women is off-label and largely unstudied outside PAH; tolerability at 20 mg daily was poorer in women (Ölmestig 2025).

Interaction with Foundational Habits

  • Sleep: No direct effect is established; insomnia appears only among uncommon adverse events (under 2%) in the label (CIALIS FDA label). Evening dosing places peak levels, and any headache or nasal congestion, overnight; this timing effect on sleep is practical, not studied.
  • Nutrition: Neutral for absorption, as food does not change uptake (CIALIS FDA label). Strengthening interactions are plausible with grapefruit (higher exposure) and nitrate-rich concentrates (more vessel widening); heavy alcohol on dosing days deepens blood-pressure falls.
  • Exercise: No proven performance gain. In mountaineers prone to altitude lung edema, tadalafil lowered lung artery pressure and edema incidence (Maggiorini 2006) but did not improve exercise capacity (Fischler 2009). In stable coronary disease, exercise time to ischemia (reduced heart blood flow) was unchanged (CIALIS FDA label).
  • Stress management: Indirect: no cortisol data exist, but psychogenic ED (of psychological origin) improved markedly with daily 5 mg (Porst 2014), and tadalafil improved psychological outcomes and sexual confidence more than sildenafil (Gong 2017); effects on anxiety itself were not measured.

Monitoring Protocol & Defining Success

Baseline assessment before starting covers seated and standing blood pressure, kidney function (creatinine clearance or estimated glomerular filtration rate, eGFR), a liver panel, HbA1c, and validated symptom scores for erectile function and urinary symptoms; men planning conception can add a semen analysis. A review of all medications for nitrates, alpha-blockers and CYP3A4 inhibitors, and of eye history for prior NAION or retinal disease, completes the baseline.

Ongoing monitoring follows this cadence: standing blood pressure and symptom scores at 1 week and 4 weeks after starting or changing dose, then blood pressure, kidney function and symptom scores every 6–12 months; HbA1c every 6–12 months in people with diabetes; a repeat semen analysis after about 3 months of use in men planning conception. Success means a meaningful change in the targeted symptoms without orthostatic symptoms.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure (seated and standing) Resting at or above 90/50 mm Hg (CIALIS FDA label threshold) Safety check: hypotension stops or changes use Standard adult reference below 120/80 mm Hg; check standing drop after 2–3 minutes, especially with alpha-blockers; threshold from CIALIS FDA label
Creatinine clearance or eGFR Creatinine clearance above 50 mL/min for standard dosing (CIALIS FDA label) Safety check: low values change or rule out daily dose Standard eGFR reference 90 mL/min/1.73 m² or higher; 30–50 mL/min means 2.5 mg start, below 30 no daily use (CIALIS FDA label); no fasting needed
Liver panel (ALT, bilirubin, albumin) ALT 7–56 U/L (standard reference range) Safety check: severe impairment rules out use ALT (alanine aminotransferase, a liver enzyme); Child-Pugh Class C excludes use; Class A–B limits as-needed dose to 10 mg (CIALIS FDA label); fasting improves bilirubin accuracy
IIEF-EF score No established target; track change from own baseline Expected to change with treatment A gain of 4 or more points was the minimal clinically important difference (MCID, smallest change patients notice) in Porst 2014; score before and after 12 weeks
IPSS No established target; track change from own baseline Expected to change in men with prostate symptoms Trial gains about 2–3 points beyond placebo (Oelke 2012); pair with urine-flow history and nocturia (night-time urination) count
HbA1c 4.0–5.6% (standard reference range) Expected to change modestly in type 2 diabetes Evidence from two small RCTs (Fryk 2023); no fasting needed; reflects about three months
Semen analysis (if planning conception) Sperm concentration 16 million/mL or more (standard reference range) Safety check: falls may prompt stopping Daily 20 mg lowered concentration in some men, reversible after stopping (Hellstrom 2008); 2–7 days abstinence before sampling

Qualitative markers:

  • Erection quality, morning erections and sexual confidence
  • Urinary stream, urgency and night-time urination
  • Headache, indigestion, back or muscle pain after doses
  • Dizziness or light-headedness on standing
  • Any change in vision (including blue-tinged or blurred vision) or hearing
  • Exercise tolerance and sense of circulation in hands and feet

Emerging Research

  • Tadalafil in early Alzheimer disease: NCT07172815, Imperial College London, phase 2, 244 participants, one-year safety and tolerability primary endpoint, not yet recruiting (completion 2028). A positive result would strengthen the Low dementia grade; a null result would weaken it further.
  • Glucose tolerance in prediabetes: NCT05051436, phase 4, 96 participants, tadalafil 10 mg versus mirabegron (a bladder-relaxing drug) versus placebo, oral glucose tolerance primary endpoint, recruiting (completion 2027). A positive result would extend the glycemic benefit beyond diabetes; a null result would confine it to diabetes.
  • Daily low dose in mild cognitive impairment: NCT07882901, phase 2, 44 older adults, tadalafil 5 mg, adherence primary endpoint with cognition and cerebral vasomotor reactivity (brain-vessel widening capacity), not yet recruiting. Positive results would support larger cognitive trials; null results would weaken the brain-perfusion rationale.
  • ETLAS-2 sub-studies: NCT05173896 reached primary completion in 2024 and remains active, not recruiting (completion 2029); published results showed poor adherence to 20 mg daily and no cognitive difference at 3 months (Ölmestig 2025, Ölmestig 2025). Positive imaging sub-studies would support lower-dose trials; null results would weaken the brain-protection case.
  • Pulmonary hypertension in chronic lung disease: NCT05844462, phase 3, 200 participants with severe pulmonary hypertension from chronic obstructive pulmonary disease (COPD, a smoking-related lung disease), recruiting (completion 2027). A positive result would add a lung indication; a null result would leave the conclusion unchanged.
  • Outcome trials needed: No randomized trial of cardiovascular events or mortality exists; the meta-analysis authors called for one (Soulaidopoulos 2024), and Kloner notes that generic availability leaves manufacturers little incentive to fund such trials (NPR report).
  • Safety signals: Updated pooling found a class-wide melanoma association without a significant tadalafil-specific estimate (Kreuz 2025); larger tadalafil-specific cohorts could confirm or dismiss it.
  • Cerebral small vessel disease: A 2026 meta-analysis of four RCTs in cerebral small vessel disease (damage to the brain’s tiny arteries) found higher white-matter blood flow but no cognitive benefit (Yan 2026); lower-dose, longer trials could strengthen or weaken the brain-protection case.

Conclusion

Tadalafil is a long-acting prescription drug that widens blood vessels by protecting a natural relaxing signal. For health-focused adults, its firmest benefits are better erections and easier urination in men with an enlarged prostate, backed by many well-run trials. Smaller trials add modestly lower blood sugar in people with diabetes, and the drug is an established treatment for a rare disease of the lung arteries.

The longevity case rests on a different kind of evidence. Large health-record studies link the drug to fewer heart attacks and deaths, but they compare men who chose treatment with men who did not, so healthier habits may explain part of the gap. Studies of dementia point in both directions, and trials of blood-vessel lining function disagree.

The main risks are common and mostly mild: headache, indigestion and back or muscle aches, more so at higher doses. Dangerous drops in blood pressure occur when it is combined with heart-pain drugs called nitrates and with some prostate and blood-pressure drugs or heavy drinking. Rare reports of sudden vision or hearing loss and a weak skin-cancer association remain unconfirmed as causes, while long daily use slightly lowered sperm counts in some men, mostly reversibly.

Much of the clinical evidence was funded by the manufacturers, and some clinics that promote daily use for longevity also sell it. Overall, tadalafil is well characterized as a treatment for its approved conditions, while its value as a longevity drug remains plausible but uncertain.

Top - Benefits - Risks - Protocol